Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); OraQuick HIV-OTC Test in 30,000 Locations

July 6, 2012 9:00 AM EDT Send to a Friend
Get Alerts OSUR Hot Sheet
Price: $4.35 -0.91%

Rating Summary:
    11 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 28 | New: 14
Trade OSUR Now!
Canaccord Genuity reiterates a 'Buy' on OraSure Technologies (NASDAQ: OSUR) price target of $14.00.

Analyst, Jeffrey Frelick, said, "Reiterate our rating following FDA approval of the OraQuick HIV-OTC test, the first rapid OTC test approved for HIV...OSUR expects to sell into 20-25 different retailers across 30,000 locations, including Walgreens (NYSE: WAG), CVS (NYSE: CVS), Wal-Mart (NYSE: WMT), Rite Aid (NYSE: RAD) and Kroger (NYSE: KR), and expects to reach a large percentage of its audience through retail store circulars. One retailer agreed to include a sign at the pharmacy to market the test...We expect OSUR will record $7.0M in sales in 2013 assuming an ASP of $35 and modest 0.4% penetration rate."

For an analyst ratings summary and ratings history on OraSure Technologies click here. For more ratings news on OraSure Technologies click here.

Shares of OraSure Technologies closed at $13.36 yesterday, with a 52 week range of $6.29-$13.65.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here



You May Also Be Interested In


Related Categories

Analyst Comments, FDA

Related Entities

Canaccord Genuity

Add Your Comment